Efficacy of low-dose semaglutide added to metformin on clinical and metabolic parameters in women with polyendocrine metabolic ovarian syndrome and obesity: A phase II randomized controlled trial
Background: Obesity exacerbates metabolic and androgenic abnormalities in polycystic ovary syndrome (PCOS). Although metformin is widely used, its effects on weight and metabolic dysfunction are modest. Semaglutide may offer additional benefit, but evidence in South Asian women with PCOS and obesity is limited. Objecti...